Galapagos NV

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Galapagos NV
Formerly called
Galapagos Genomics NV
Naamloze vennootschap
Traded as EuronextGLPG
Industry Pharmaceutical
Founded 1999
Headquarters Mechelen, Belgium
Key people
Onno van de Stolpe (CEO), Raj Parekh (Chairman)
Products filgotinib; GLPG1205; GLPG0778
Revenue €151.6 million (2016)[1]
Profit €54.0 million (2016)[1]
Total assets €1,083 million (end 2016)[1]
Total equity €758.7 million (end 2016)[1]
Number of employees
508 (end 2016)[1]

Galapagos NV (formerly known as Galapagos Genomics) is a Belgo-Dutch pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville and Zagreb. The CEO is the Dutchman Onno van de Stolpe.

Currently it is developing drugs against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.[2]


Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec.[3] The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.[4]

The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.

Drugs currently under development[edit]

External links[edit]

Coordinates: 51°03′19″N 4°27′08″E / 51.05528°N 4.45222°E / 51.05528; 4.45222

See also[edit]


  1. ^ a b c d e "Galapagos Annual Report 2016". Galapagos. Retrieved 27 March 2017. 
  2. ^ Todd Campbel (9 June 2016). "Why Galapagos NV Shares Soared 30.5% in May". The Motley Fool. 
  3. ^ "History". Galapagos. 
  4. ^ "Galapagos Genomics gaat zelf medicijnen ontwikkelen" [Galapagos Genomics to develop medicines themselves]. Het Nieuwsblad (in Dutch). 16 April 2005.